Vascular access device selection survey
Abstract:
Aims: The PRACTICE survey aimed to characterize vascular access device (VAD) practices for systemic anti-cancer therapy (SACT) across Europe, addressing gaps in clinician decision-making, training, and complication management.
Methods: Conducted as a cross-sectional survey from May to October 2024, the study engaged healthcare professionals (HCPs) from 18 European countries, with 403 completing demographic questions and 166 responding to procedural and training-related queries.
Results: Results revealed significant variability in VAD selection, influenced by institutional protocols, geographic location, and the presence of vascular access teams (VATs). Oncologists were identified as primary decision-makers (36%), though nursing staff played a pivotal role in daily management. Peripheral intravenous catheters (PIVCs) dominated in Ireland and Finland (43-49%), while tunnelled implantable devices (TIVADs) were preferred in Belgium (65%). Barriers to optimal VAD selection included insufficient training (80% sought further education) and inconsistent guideline adoption (51% reported institutional protocols).
Conclusion: The study underscores the need for standardised practices, interdisciplinary collaboration, and enhanced training. Findings highlight opportunities for integrating VAD selection into cancer care certification metrics and fostering partnerships between oncology and vascular access societies.
Reference:
Duggan C, Hernon O, Simpkin AJ, Manasek V, de la Torre-Montero JC, Santos-Costa P, Moss JG, Ruhlmann CH, Taxbro K, Rodriguez-Calero MA, Oom R, Barroca R, Grady OO, Daly J, Blanco-Mavillard I, Dodlek N, Charvát J, Unanue-Arza S, Krakovska B, Carr PJ. Promoting a Research Agenda for Cancer Treatment for Intravenous Devices with Clinicians in Europe; the PRACTICE survey. J Cancer Policy. 2025 Sep 22:100643. doi: 10.1016/j.jcpo.2025.100643. Epub ahead of print. PMID: 40992565.